Dr. Debra M. Prow
Claim this profileMcFarland Clinic PC - Ames
Expert in Parotid Gland Cancer
Expert in Lung Cancer
125 reported clinical trials
185 drugs studied
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Debra M. Prow is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
More about Debra M. Prow
Clinical Trial Related6 years of experience running clinical trials · Led 125 trials as a Principal Investigator · 53 Active Clinical TrialsTreatments Debra M. Prow has experience with
- Nivolumab
- Carboplatin
- Pembrolizumab
- Atezolizumab
- Ipilimumab
- Paclitaxel
Breakdown of trials Debra M. Prow has run
Parotid Gland Cancer
Lung Cancer
Cervical Adenocarcinoma
Non-Small Cell Lung Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Debra M. Prow specialize in?
Is Debra M. Prow currently recruiting for clinical trials?
Are there any treatments that Debra M. Prow has studied deeply?
What is the best way to schedule an appointment with Debra M. Prow?
What is the office address of Debra M. Prow?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.